Значение прогностических факторов при лечении больных фиброзной крупноклеточной В-клеточной лимфомой антрациклинсодержащими режимами химиотерапии
Диссертация
Массивным поражением («bulky») принято считать любые опухолевые образования диаметром более 10 см. Для определения массивного поражения лимфоузлов средостения введен медиастинально-торакальный индекс (МТИ) — отношение максимальной ширины тени средостения к диаметру грудной клетки в самом широком ее месте, на уровне Th V-VH. Согласно этому определению, массивным («bulky») поражением предложено… Читать ещё >
Список литературы
- Абдылдаев Р.А., Круглова Г. В. Факторы прогноза при лимфосаркомах. Тер. Архив 1987- 6: стр 43−46.
- Бредер В.В., Горбунова В. А., Бесова Н. С. Анемия при злокачественных опухолях. Современная онкология, 2002- № 3- том 4: стр 134−136.
- Внутренние болезни под редакцией Тинсли Р. Харрисона (Harrison’s principles of internal medicine). 2002г- часть 6- раздел 2, ИЗ: стр 838−862.
- Волкова М.А., Поддубная И. В. Заведос (идарубицин) в лечении гемобластозов. М 2002: стр 72−82.
- Гублер Е.В., Генкин А. А. Применение непараметрических критериев статистики в медико-биологических исследованиях. Отнесение наблюдений к одному из двух возможных классов (диагностика и прогнозирование). Ленинград 1973- гл 4: стр 62−85.
- Давыдов М.И., в Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2001 г.
- Давыдов М.И., Демидов Л. В. Основы современной онкологии. М 2002г: стр 170−82.
- Круглова Г. В., Пробатова Н. А., Шмакова Э. Д. и соавт. Результаты полихимиотерапии различных вариантов лимфосарком по классификации Всемирной Организации Здравоохранения. Пробл. Гемат. 1983- 4: стр 3−7.
- Курильников А.Я. Мабтера первые моноклональные антитела в терапии неходжкинских лимфом. Современнаяонкология, экстра-выпуск по материалам журнала за 1999−2002 гг. 2003: стр 3−4.
- Лукьянова Е.А. Медицинская статистика. Дисперсионный анализ. М 2002: стр 183−194.
- Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ESMO). М 2003: стр 25−30.
- Мулле И., Саль Г., Кетгерер Н. Частота и значение анемии у больных с неходжкинскими лимфомами. В центре внимания анемия у онкологичеких больных, расширенные тезисы докладов. М 2002- том 1- выпуск 1: стр 19−21.
- Новые подходы к терапии неходжкинских лимфом. Заведос (идарубицин), под редакцией Ф. Кабаннилас, Л. Линч. М -1998- сгр 26.
- Пивник А.В. Лечение злокачественных лимфом. Российский Медицинский Журнал. 1999- № 10- том 7: стр 465−469.
- Поддубная И.В. Неходжкинские лимфомы. Клиническая онкогематология под ред. Волковой М. А. М 2001- гл 23: стр 336 375.
- Поддубная И.В. Реальность и перспективы лекарственной терапии неходжкинских лимфом. Современная онкология, экстра-выпуск по материалам журнала за 1999−2002 гг. 2003: стр 16−20.
- Поддубная И.В., Курильников А. Я., Османов Д. Ш. Применение Мабтеры (ритуксимаба) с антрациклинсодержащими комбинациями химиопрепаратов в качестве первой линии лечения больных В-клеточными НХЛ с неблагоприятным прогнозом.
- Современная онкология, экстра-выпуск по материалам журнала за 1999−2002 гг. 2003- стр 3.
- Подцубная И.В., Османов Д. Ш., Курильников А. Я. Мабтера в терапии неходжкинских лимфом высокой степени злокачественности: схема R-CHOP. Современная онкология, экстравыпуск по материалам журнала за 1999−2002гг. 2003- стр 13.
- Подцубная И.В., Османов Д. Ш., Пробатова Н. А., Тупицин Н. Н., Круглова Г. В., Курильников А. Я. Новые возможности в терапии зрелоклеточных неходжкинских лимфом: препарат «Мабтера» настоящее и будущее. Современная онкология 2001- № 2- томЗ: стр 57−60.
- Подцубная И.В. Обоснование лечебной тактики при неходжкинских лимфомах. Современная онкология /тематическая вставка/. 2002- № 1- том 4: стр 3−7.
- Пробатова Н.А. Морфологические критерии диагностики злокачественных лимфом. Клиническая онкогематология под ред. Волковой М. А., М 2001- гл. 21: стр 306 307.
- Птушкин В.В. Особенности лечения агрессивных НХЛ у пожилых пациентов. Современная онкология, экстра-выпуск по материалам журнала за 1999−2002.2003: стр 5−6.
- Реброва О.Ю. Анализ времени до наступления исхода. Статистический анализ медицинских данных, применение прикладных программ statistica. М 2002- гл 15.4: стр 238−246.
- Реброва О.Ю. Многофакторный анализ данных. Статистический анализ медицинских данных, применение прикладных программ statistica. М 2002- гл 13: стр 198−210.
- Стентон Гланц. Медико-биологическая статистика. Дисперсионный анализ. Практика 1998: стр 47−63.
- Чиссов В.И. Основные показатели состояния специализированной онкологической помощи населению России в 2002г. М-2003.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N.Engl. J. Med.-1993- 329: 987.
- Akerman M, Brandt Z, Johnson A et al. Mitotic activity in non-Hodgkin's lymphoma. Relation to Kiel classification and to prognosis. Br.J.Cancer 1987- 55,2:219−223.
- Alici S, Bavbek SE, Kaytan E, Eralp Y, Argon A, Onat H. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. Proceedings of ASCO. 2001- Vol 20- 206b: 2641.
- Anderson T, Chabner В A, Young RC et al. Malignant lymphoma. I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982- 50:2699−2707.
- Ansell S. M., Falkson G., van der Merwe R., Uys A. Chronological age is multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. Ann. Oncol. -1992- 3: 45−50.
- Armitage J.O., Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984- Apr- 32(4):269−73.
- Armitage J.O. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas. Clin lymphoma. 2002 Dec- 3 Suppl 1: S5−11.
- Ascari E, Gobbi PG. Prognostic factors in malignant lymphomas (Hodgkin and non-Hodgkin). Acta haematol. 1987/1988- 78 (suppl 1): 146−150.
- Aviles A, Neri N, Huerta-Guzman J. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients. J Surg Oncol. 2002 Jun- 80(2): 111−5.
- Balzarottil M, Spina M, Sarinal B, Magagnolil M, Castagnal L, Milan I, Ripal С et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Annals of Oncology 2002- 13:1341−1346.
- Bernascont C, Brusamolino E, Lazzarimo M et al. Lymphoblastic lymphoma in adults: a study on 30 patients treater with two different programs according to bone marrow findings. Tumori 1984- 70: 355−362.
- Bertini M, Boccomini C, Calvi R. The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma. 2001 Mar- 1 (4): 278−84.
- Binn M, Ruskone-Fourmestraux A, Lepage E, Haioun C, Delmer A et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Annals of Oncology 2003- 14:1751−1757.
- Bonadonna G, Saccani JG. Prognostic factors and respons to treatment in non-Hodgkin's lymphoma. Anticancer Res. 1987- 7,4: 685 694.
- Brittinger G, Bartels H, Common H et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas. Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Haematological Oncology 1984- 2:269−306.
- Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra I et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003 Jan- 14(1): 140−51.
- Cabanillas F, VelasquesWS, Hagemeister FB, McLaughlin P, Redman JR: Clinical biologic and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992- 79:1024−1028.
- Cavalli F. Proc. ASCO-1995. Abstr.714.
- Cerny T, Betticher D. Role of high-dose therapy in diffuse large B-cell lymphoma. Ann Oncol 2000- 3: 117−121.
- Cerny T, Gillessen S. Advances in the treatment of non-Hodgkin's lymphoma. Eur Soc for Med Oncol 2002: 211−216.
- Coiffier B, Bryon PA, French M, Blanc M, Sebban C, Berger F, Viala JJ. Intensive chemotherapy in aggressive lymphomas:
- Updated results of LNH-80 protocol and prognostic factors affecting response and survival. Blood 1987- 70: 1394−1399.
- Coiffier В., Haioun C., Ketterer N. et al. Rituximab (anti -CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase П study. Blood 1998- Vol. 92:1927−1932.
- Coiffier B, Lepage E, Brier J, Herbrecht R, Tilly H, Bouabdallan R, Morel P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med 2002- 346(4):235−42.
- Coltman CA, Dahlberg S, Jones SE, Miller TP, Dana BW, McLekvey EM et al. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 1986- 5:197.
- Conconi A, Zucca E, Roggero E, Bertoni F et al. Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol. 2000 Jun- 18 (2): 61−73.
- Connors J.M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions- 1987 update and additional observations. Sem. Hemat. 1988- Vol. 25: P 41.
- Cooper IA, Wolf MM, Robertson TI, Fox RM et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994- 12: 769−778.
- Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, Deakin DP, Crowther D. Prognostic factors in high and intermediate-grade non-Hodgkin's lymphoma. Br J Cancer 1989- 59: 276 282.
- D’Amore F, Brincker H, Christensen BE, Thorling К et al. Non-Hodgkin's lymphoma in the elderly. Ann Oncol 2002- 3: 379−386.
- Dana WB, Dahlberg S, Miller TP, Hartsock RJ, Balcerzak S et al. m-BACOD treatment for intermediate and high-grade malignant lymphomas: A Southwest Oncology Group phase П trial. J Clin Oncol 1990- 8:1155−1162.
- Davis ТА, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol. 1999- 17:1851−1857.
- Effect of age on the characteristics and clinical behavior of Non-Hodgkin's Lymphoma patients. The non-Hodgkin's Lymphoma Classification Project. Ann. Oncol. 1997- 8: 973.
- Elias L. Differences in age and sex distributions amond patients with non-Hodgkin's Lymphoma. Cancer. 1979- 43: 2540.
- Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M et al. Survival of diffuse large-cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990- 66: 1124−1129.
- Ersboll I, Schulir HB, Thomsen BLR et al. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence risk factors and treatment. Scand. J. Haematol. 1985- 35,5: 487−496.
- Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002- 58: 1513−1520.
- Fisher R. J., Gaynor E. R., Dahlberg S. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993- 328: 1002−6.
- Fisher R. I, Shah P. Current trends in large cell lymphoma. Leukemia. 2003 Oct- 17 (10): 1948−60.
- Fisher R.I., Miller T. P, Dana B.W. et al. Southwest Oncology Group clinical trials for intermediate and high-grade non-Hodgkin's lymphomas. Sem. Hematol 1987- Vol 24- No 2 (suppl 1): 2125.
- Gallagher CG, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 1986- 4,10:1470−1480.
- Gams RA, Rainey M, Dandy M, Bartolucci AA, Silberman H, Omura G. Phase III study of BCOP v CHOP in unfavorable categoriesof malignant lymphoma: a Southeastern Cancer Study Group trial. J Clin Oncol 1985- 3:1188−95.
- Gaynor ER, Fisher RI. Lymphomas-lst ed./ Ed. G. Canellos, ТА Lister, JL.Sclar.-Philadelphia-London: WB Sanders Сотр., 1998: p.399−413.
- Gobbi PG, Ricevuti G, Balduini С et al. Prognostic factors in non-Hodgkin's lymphomas. Acta haematol. 1985/1986- 74,2: 86−91.
- Gongalves E, Afonso N, Viterbo L, Henrique R et al. Diffuse large B-cell lymphoma clinical prognostic factors. Annals of Oncol 2002- 13- abst 532.
- Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. NEngl J Med 1992- 327:1342−49.
- Grogan L, Corbally N, Dervan AP, Byrne A, Carney ND: Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose Adriamycin-based regimens. Ann Oncol 1993- 5 (suppl 2): S57-S51.
- Harberg H, Bjorkholm M, Glimelius B, Lindemalm C, Mellstedt H, Killander A. CHOP vs MEV for the treatment of non
- Hodgkin’s lymphoma of unfavorable histopatology: a randomized clinical trial. Eur J Cancer Clin Oncol 1985- 21:175−179.
- Harris NL, Jaffe ES, Stein H, et al. A revised European -American classification of lymphoid neoplasms: a proposal form the International Lymphoma Study Group. Blood 1994- vol.84: 1361−92.
- Harris NL. World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. Clin.Oncol., 1999- 17(12): 3835−49.
- Hartge P., Devesa S.S., Praumeni J.F. et al. Hodgkin’s and non-Hodgkin's lymphoma. IN: Cold Spring Harbor Laboratory Press. Cancer Surv. 1994- 19,20: 423−453.
- Hoerni B, Bonichon F, Coindre JM et al. Prognostic des lymphomas folliculares dans une serie de 180 cas. Bull. Cancer 1986- 73,2:171−177.
- Hoerni В., Bonichon F., Coindre JM et al. Prognostic des lymphomas folliculaires dans une serie de 180 cas. Bull Cancer 1986- 73,2: p 171−177.
- Horning SH, Doggett RS, Warlike RA et al. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood 1984- 63,5:1209−1215.
- Hoskins PJ, Ng V, Spinelli JJ, Klimo P, Connors JM. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991:9: 220−226.
- Hui P., Feller A., Lennert K. Histopatology., 1998- Vol. 12- N2: 127−145.
- Ibrahim EM, Ezzat A, Weichi EI, Martin J, Khafaga Y et al. Primary Intestinal Diffuse Large B-Cell Non-Hodgkin's Lymphoma: Clinical Features, Management, and Prognosis of 66 Patients. Proceedings of ASCO. 2001- Vol 20- 296a: 1182.
- Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A et al. CHOP versus MACOP-B in aggressive lymphoma a Nordic Lymphoma Group randomized trial. Arm Oncol 1999- 10: 1079−86.
- Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Ass., 1958- 53: p 457−481.
- Longo DL, DeVita VT, Duffey PL, Wesley MN et al. Superiority of Pro-MACE-Cyta-BOM over Pro-MACE-MOPP in thetreatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991: 9: 25−38.
- Lopez-Guillermo A, Montserrat E, Reverter JC, Cervantes F et al. Large-cell lymphoma: A study of prognostic factors and assessment of five recently proposed predictive systems. Leuc Lymphoma 1993: 10: 101−109.
- Louis B. Harrisona, Manjeet Chadhaa, Richard J et al. Impact of Tumour Hypoxia and Anemia on Radiation Therapy Outcomes. The Oncologist, Dec 2002- Vol 7- No 6: 492−508,
- Lukes RG, Collins RD. Immunologic classification of human malignant lymphomas. Cancer 1974- 34:1488−03.
- Mazza Р, Gherlinzani F, Kemna G et al. Clinicopathological study on non-Hodgkin's lymphomas. Haematologica 1987- 72,4: 351 357.
- McLaughlin Р, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998- 16: 2825−2833.
- Meusers Р, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg К et al. Multicenter randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989- 7: 365−380.
- Miller H. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. ASCO 2001- Abstr. 3024.
- Moller MB, Christensen BE, Pedersen NT. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer. 2003 Aug 1- 98(3): 516−21.
- Montotol S, Lopez-Guillermol A, Ferrerl A, Camosl M et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology 2002- 13: 523−530.
- Montserrat E, Garcia-Conde J, Vinolas N, Lopez-Guillermo A et al. CHOP vs ProMACE-CytaBOM in the treatment of aggressivenon-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. Eur J Haematol 1996- 57: 377−383.
- Morel P, Lepage E, Brice P, Dupries В et al. Prognosis and treatment of lymphoblastic lymphoma in ad ults: a report on 80 patients. J Clin Oncol 1992 Jul- 10 (7): 1078−85.
- Mori M, Kitamura K, Masuda M, Hotta T et al. Prognostic Factors in Elderly with Non-Hodgkin's Lymphoma: Development of a model to Predict Survival. Proceedings of ASCO. 1999- Vol 18- 13a: 46.
- Moullet I., Salles G, Ketterer N, Dumontet C, Bouafia F, Coiffier В et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998- 9:1109−15.
- Nakamine H, Bagin RG, Vose JM, Bast MA, Bierman PJ, Armitage JO, Weisenburger DD. Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma. Cancer 1993: 71: 3130−3137.
- Nancy Lee Harris, Elaine SJaffe, Jacques Diebold, Georges Flandrin, H. Konrad Muller-Hermelink, James Vardiman, T. Andrew Lister and Clara D.Bloomfeld. J.Clin.Oncol 1999- 17: 3835−49 by American Society of Clinical Oncology.
- Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P et al. Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin's Lymphoma Prognostic Index. Oncology 1998- 55(5): 405−415.
- O’Reilly S.E., Hoskins P., Klimo P. et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin’s disease/Ann. OncoL 1991- Vol. 2 (suppl 1): 17−23.
- Pan L, Bevertly PCL, Isaacson PG. Lactate dehydrogenase (LDH) isoenzymes and proliferative activity of lymphoid cells. An immunocytochemical study. Clin Exp Immunol 1991- 86: 240−245.
- Pavlovsky S, Santarelli MT, Erazo A et al. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol 1992- 3:205−209.
- Pereira A. Cervantes F, Montserrat E, Llebaria C, Rozman C: non-Hodgkin's lymphoma of unfavorable histology: A multivariate analysis of factors predicting the response to CHOP. Hematol Oncol 1987−5:203−211.
- Pfreundschuh M., Kloess M. et al. 2-Weekly Chop (CHOP-14): The New Standard Regimen for Patients with aggressive Non-Hodgkin's Lymphoma (NHL)>60 year of Age. Proc. ASH 2001- Abstr 3027.
- Pfreundschuh M., Trumper L, Kloess M. et al. Two-weekly CHOP (CHOP-14): new standard regimen for patients with aggressive Non-Hodgkins lymphoma. Ann Oncol 2002- 13 (supp 2): Abstr 81.
- Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jader U et al. Chemotherapy for management of localized high-grade gastric B-cell lymphoma: how much is necessary? Ann. Oncol., July 1, 2002- 13 (7): 1094−1098.
- Ramakrishnan G, Nair R, Mirchandaney K, Naresh KN, Advani MH et al. Alternating Triple Therapy (CHOP-MINE-ESHAP) in Large Cell В Phenotype, Non-Hodgkin's Lymphoma. Proceedings of ASCO. 2001- Vol 20- 291a: 1160.
- Reis L.A.G., Miller B.A., Hankey B.F., et al., SEER Cancer Statistics Review (1973−1991): Tables and Graphs.- Bethesda: National Cancer Institute, NIH Publication № 94−2789, MD US Department at Health and Human Services, 1994
- Ribrag V, Koscielny S, Carpiuc I et al. Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. Leukemia. 2003 May- 17(5): 972−7.
- Richard В Wilder, Maria A Rodriguez, L Jeffrey Medeiros, Susan L Tucker et al. International Prognostic index-Based Outcomes for Diffuse Large B-cell Lymphomas. Cancer, June 15,2002- vol 94:12.
- Romejko-Jarosinska, Poplawska-Szezyglowska, Mioduszewska et al. Primary testicular lymphoma Clinical presentationand outcome. Report of 21 patients from single centre. Annals of Oncology. 2002- Vol 13 (Supp 5): P441.
- Rudders RA, Kaddis M, De Lellis RA et al. Nodular non-Hodgkin's lymphoma (NHL): Factors influencing prognosis and indicators for aggressive treatment. Cancer 1979- 43:1643−51.
- Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma. Ann Oncol 2000- 11: 373−375.
- Salles G. Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma. Annals of Oncology. 1996- 7: 993−996,.
- Sana S, Aziz Z. Applicabilliti of International prognostic index in non-Hodgkin's lymphoma. Proceedings of ASCO. 2001- Vol 20- 206b:2642.
- Scarin A.T., Cannellos G.P., Rosenthal D.S. et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J.Clin. Oncol.-1983- 2: 91−98.
- Scarin A.T., Cannellos G.P., Rosenthal D.S. et al. J.Clin. Oncol.-1986- Vol.4: p 57.
- Schneider MA, Strauss JD, Schluger EA, Lowenthal AD et al. Treatment results with an aggressive chemotherapy regimen (MACOP-B) for intermediate and some high grade non-Hodgkin's lymphomas. J Clin Oncol 1990: 8: 94−102.
- Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986:104:777−765.
- Sibtain A, Wilson GD, Honess DJ, Hoskin PJ et al. Tumour Hypoxia and Vascularity in Lymphoma. Annals of oncology 2002- vol 13 (supp 2): 615.
- Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 1990: 8: 986−993.
- Solal Celigny P., Cbastang C., Herrerat. et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am. J. Med.- 1987- 83: 1075−9.
- Sonneveld P., de Ridder M., van der Lelie H. et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol.- 1995- 13:2530−39.
- Stein RS, Greer JP, Flexner JM, Hainsworth JD et al. Large cell lymphomas. Clinical and prognostic features. J Clin Oncol 1990: 8: 1370−1379.
- Straus DJ, Gaynor JJ, Lieberman PH et al. Non-Hodgkin's lymphomas: Characteristics of long-term survivals following conservative treatment. Am. J. Med 1987- 82,2:247−256.
- Takagi T, Sampi K, Sawada U, Sakai C, Oguro M. A comparative study of CHOP versus MEVP therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study. Int J Hematol 1993- 57: 67−71.
- Tilly H, Coiffier B, Casasnovas О et al. Survival advantage of ACVB regimen over standard CHOP in the treatment of advanced aggressive Non-Hodgkin's lymphoma. The LNH93−5 study. Ann Oncol 2002- 13 (supp 2): Abstr 82.
- Trumper L, Pfreundschuh M Therapeutic strategies for aggressive lymphomas. 5th Congress of the European Hematology Association Educational Book, UK, 25−28 June 2000:19−23.
- Tsavaris N, Kosmas C, Vadiaca M, Giannouli S et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages П1ЯУ) non-Hodgkin's lymphoma. Anticancer Res. 2002 May-Jun- 22 (3): 1845−8.
- Ulusakarya A, Koscielny S, Vantelon J, Casiraghi О et al. Primary Mediastinal Diffuse Large Cell Lymphoma in 119 Patients of a Single Institution: Prognostic Features and Role of Radiotherapy. Proceedings of ASCO. 1999- Vol 18- 15a: 53.
- Van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001- 19: 1855−1864.
- Velasques WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR et al. Risk classification as the basis for clinical staging of diffuse large cell lymphoma derived for 10 year survival data. Blood 1989−74:551−557.
- Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995- 332:1045−51.
- Vitolo U, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E et al. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992- 10: 219−227.
- Vose JM, Armitage JO, Weisenburger DD. The importance of age in survival in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1986:4: 295−305.
- Waits TM, Greco A, Greer JP, Johnson DH, Wolff SN, Stein RS et al. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. J Clin Oncol 1993- 11: 939−949.
- Weick J.K., Dahlberg S., Fisher R. I. et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J. Clin. Oncol. 1991- May 9(5): 748−53.
- Wilder RB, Rodrigues MA, Medeiros LJ et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer. 2002 Jun 15- 94(12): 3083−8.
- Wilson WH, Frankel SR, Drbohlav N, Hegde U, Gutierrez M et al. Phas II Study of Dose-Adjusted EPOCH-Rituximab in Untreated High Risk Large B-Cell Lymphomas. Proceedings of ASCO. 2001- Vol 20- 290a: 1158.
- Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, April 15,2002- 99 (8): 2685−2693.
- Wolf M, Matthews JP, Stone J, Cooper IA, Robertson TI, Fox RM. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 1997- 8 (Suppl 1): 71−75.
- Yan Y, Chan WC, Weisenburger DD, Anderson Ж et al. Clinical and prognostic significance of bone marrow involvement inpatients with diffuse aggressive B-cell lymphoma. J Clin Oncol. 1995 Jun- 13 (6): 1336−42.
- Zinzani PL, Martelli M, Storti S, Musso M, Cantonetti M, Leone G et al. Phase П1 comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995- 19: 329−335.